Summary
Biogen Inc. (BIIB) has filed a Form 8-K on February 12, 2025, to report its financial results for the fourth quarter and full year ended December 31, 2024. The primary purpose of this filing is to provide investors with the company's performance data, which was announced via a press release furnished as Exhibit 99.1. Investors should refer to this press release for specific details on revenue, earnings, and other key financial metrics, as well as management's commentary on the results and outlook.
Key Highlights
- 1Biogen Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, via an 8-K filing on February 12, 2025.
- 2The filing includes a press release (Exhibit 99.1) containing detailed operational and financial performance information.
- 3Investors can access specific financial metrics, such as revenue and earnings, from the furnished press release.
- 4The report is being furnished under Item 2.02, meaning it provides information but is not considered 'filed' for all purposes under the Exchange Act.
- 5The filing also includes the Cover Page Interactive Data File in XBRL format.
Frequently Asked Questions
The specific financial results, including revenue, earnings, and other performance metrics for the fourth quarter and full year ended December 31, 2024, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing.
No, this Form 8-K filing, specifically the press release furnished under Item 2.02, is being furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section.
Exhibit 99.1 is Biogen's press release dated February 12, 2025, which contains the core announcement of the company's results of operations and financial condition for the fourth quarter and year ended December 31, 2024. It is incorporated by reference into the filing.